Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Hristodorov, D."'
Autor:
Hristodorov, D1, Mladenov, R1, Pardo, A1, Pham, A-T1, Huhn, M1, Fischer, R2, Thepen, T3, Barth, S1
Publikováno v:
British Journal of Cancer. 9/17/2013, Vol. 109 Issue 6, p1570-1578. 9p.
Autor:
Amoury, M., Mladenov, R., Nachreiner, T., Pham, A.-T., Hristodorov, D., Di Fiore, S., Helfrich, W., Pardo, A., Fey, G., Schwenkert, M., Thepen, T., Kiessling, F., Hussain, A.F., Fischer, R., Kolberg, K., Barth, S.
Publikováno v:
International Journal of Cancer, 139(4), 916-927. Wiley
Chondroitin sulfate proteoglycan 4 (CSPG4) has been identified as a highly promising target antigen for immunotherapy of triple-negative breast cancer (TNBC). TNBC represents a highly aggressive heterogeneous group of tumors lacking expression of est
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::14bdf8567ff8638deb34096b458a236c
https://research.rug.nl/en/publications/682efef5-28e7-47b4-9b7a-01596e3acb70
https://research.rug.nl/en/publications/682efef5-28e7-47b4-9b7a-01596e3acb70
Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64+ M1 macrophages
Classical immunotoxins compromise a binding component (for example, a ligand, antibody or fragment thereof) and a cytotoxic component, usually derived from bacteria or plants (for example, Pseudomonas exotoxin A or ricin). Despite successful testing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______610::73a2934f959a7f21c3fdf4267505d553
https://publica.fraunhofer.de/handle/publica/246072
https://publica.fraunhofer.de/handle/publica/246072
Autor:
Brehm, H., Hristodorov, D., Pardo, A., Mladenov, R., Niesen, J., Fischer, R., Tur, M.K., Barth, S.
The treatment of rhabdomyosarcoma (RMS) is challenging, and the prognosis remains especially poor for high-grade RMS with metastasis. The conventional treatment of RMS is based on multi-agent chemotherapy combined with resection and radiotherapy, whi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______610::a94538ba00e0230fc0137cfb8844d857
https://publica.fraunhofer.de/handle/publica/240843
https://publica.fraunhofer.de/handle/publica/240843
Autor:
Mladenov, R., Hristodorov, D., Cremer, C., Hein, L., Kreutzer, F., Stroisch, T., Niesen, J., Brehm, H., Blume, T., Brummendorf, T.H., Jost, E., Thepen, T., Fischer, R., Stockmeyer, B., Barth, S., Stein, C.
Antibody-based immunotherapy of leukemia requires the targeting of specific antigens on the surface of blasts. The Fc gamma receptor (CD64) has been investigated in detail, and CD64-targeting immunotherapy has shown promising efficacy in the targeted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______610::630ea7c6815099ba04cb944235bf3548
https://publica.fraunhofer.de/handle/publica/242020
https://publica.fraunhofer.de/handle/publica/242020
Targeted therapies for the treatment of cancer, but also inflammation and autoimmune diseases will reduce major side effects accompanied with conventional treatment modalities. The immunotoxin concept uses bacterial or plant toxins, coupled to antibo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______610::cb4790859f77d7103ed86bbad53527a6
https://publica.fraunhofer.de/handle/publica/238818
https://publica.fraunhofer.de/handle/publica/238818
Tumor necrosis factor (TNF) is a pro-inflammatory cytokine that plays a critical role in many inflammatory diseases. Soluble TNF can be neutralized by monoclonal antibodies (mAbs), and this is a widely-used therapeutic approach. However, some patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______610::4947a0c38944080a661974bf3841aba1
https://publica.fraunhofer.de/handle/publica/238846
https://publica.fraunhofer.de/handle/publica/238846
Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL) are rare lymphoproliferative cancer types. Although most HL patients can be cured by chemo- and radio-therapy, 4-50% of patients relapse and have a poor prognosis. The need for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______610::89c21912b518c0a1e9b253c94b7aa636
https://publica.fraunhofer.de/handle/publica/236952
https://publica.fraunhofer.de/handle/publica/236952
Autor:
Schiffer, S., Letzian, S., Jost, E., Mladenov, R., Hristodorov, D., Huhn, M., Fischer, R., Barth, S., Thepen, T.
Immunotoxins are promising targeted therapeutic agents comprising an antibody-based ligand that specifically binds to diseased cells, and a pro-apoptotic protein. Toxic components from bacteria or plants can trigger a neutralizing immune response, so
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______610::008c714846afbe94d167cd4de33abb06
https://publica.fraunhofer.de/handle/publica/233546
https://publica.fraunhofer.de/handle/publica/233546
Autor:
Hristodorov, D., Mladenov, R., Pardo, A., Pham, A.-T., Huhn, M., Fischer, R., Thepen, T., Barth, S.
Background: Antibody drug conjugates (ADCs) and immunotoxins (ITs) are promising anticancer immunotherapeutics. Despite their encouraging performance in clinical trials, both ADCs and ITs often suffer from disadvantages such as stoichiometrically und
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______610::f011ece868acec48cd1d79bd16bbd8b8
https://publica.fraunhofer.de/handle/publica/233645
https://publica.fraunhofer.de/handle/publica/233645